share_log

复星医药(600196.SH):膦甲酸钠注射液获药品注册申请受理

Fosun Pharmaceutical (600196.SH): Sodium phosphonate injection accepted for drug registration application

Gelonghui Finance ·  Apr 17 04:36

Gelonghui, April 17 | Fosun Pharmaceutical (600196.SH) announced that the drug registration application for sodium phosphonate injection from the holding subsidiary Guilin Southern Pharmaceutical Co., Ltd. was recently accepted by the State Drug Administration. This new pharmaceutical chemical is intended for use in (1) cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS); and (2) acyclovir-resistant herpes simplex virus (HSV) cutaneous mucosal infections in immunodeficiency patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment